icon
icon
icon
icon
Upgrade
Upgrade

News /

Articles /

Gilead's (GILD.US) long-acting HIV therapy is set to file for approval

Market IntelWednesday, Nov 13, 2024 9:00 pm ET
1min read

Gilead Sciences (GILD.US) today announced the full results of its second pivotal Phase 3 trial, PURPOSE2, evaluating lenacapavir, a long-acting HIV capsid inhibitor, for the prevention of HIV infection. Analysis showed that up to 99.9% of participants who received lenacapavir were protected from HIV infection, and the prevention of HIV infection was superior to existing daily oral regimens. The data were presented at the International AIDS Society Conference on HIV Science and will be published in the New England Journal of Medicine. Last month, the U.S. FDA granted lenacapavir a breakthrough therapy designation for pre-exposure prophylaxis (PrEP) of HIV infection. The company expects to file a series of global regulatory applications for lenacapavir for PrEP by the end of this year.

Each year, approximately 1.3 million new HIV infections occur globally. In recent years, research has found that taking antiviral medication before becoming infected can reduce the risk of HIV infection. This prevention of HIV infection is called PrEP. The first approved HIV PrEP drug was Truvada, developed by Gilead, which is taken orally once daily and is highly effective at preventing HIV infection if taken as prescribed. Although the daily oral PrEP regimen nearly eliminates HIV infection, the high cost of the medication and the stigma associated with taking HIV-related medications limit adherence, and the actual effectiveness of the oral PrEP regimen is far below the theoretical value. Therefore, there is a significant need to develop a long-acting PrEP regimen that can increase medication adherence.

Lenacapavir (brand name Sunlenca) is a "first-in-class" long-acting HIV capsid inhibitor that interferes with the assembly and disassembly of the HIV capsid protein, acting at multiple stages of the virus life cycle.

Comments

Add a public comment...
Post
Refresh
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App